24時間受付中
Mounjaro (Tirzepatide) | Online Prescription | 2.5 mg from 6,000 JPY per pen | Consultation & Shipping Free
GIP/GLP-1 Receptor Agonist | Mounjaro Injection
Mounjaro (Tirzepatide)|Online Prescription|2.5 mg from 6,000 JPY|Consultation & Shipping Free
Once-weekly self-injection to support weight management
- Nationwide delivery, fully online flow (consultation → payment → shipping)
- Once-weekly self-injection (2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg)
- Only genuine products via authorized distributors
[Doctor’s Overview] What is the GLP-1 injection “Mounjaro”?

Mounjaro (tirzepatide) is a dual agonist acting on both GLP-1 and GIP receptors. It supports appetite control and post-meal glucose regulation, enabling sustainable weight management with a once-weekly injection. In the US, the same ingredient is approved as “Zepbound” for obesity treatment and is drawing attention in Japan as well.
Engages GLP-1/GIP to naturally reduce intake and blunt glucose spikes.
Start at 2.5 mg, escalate up to 15 mg depending on tolerability.
Consultation & standard shipping are free. Refrigerated shipping free during campaign.
How Mounjaro (GLP-1/GIP) works
This medicine enhances your body’s natural regulation of eating. It aims for gentle, sustainable change—without extreme willpower.
- Strengthens the “I’m full” signal
- Reduces hedonic snacking urges
- Helps adjust portion sizes naturally
- Slows gastric emptying
- Fullness lasts longer after meals
- Helps curb “constant hunger”
- Blunts post-meal glucose spikes
- Supports insulin response “when needed”
- Stabilizes with low hypoglycemia risk
- Shifts toward greater fat utilization
- Improves muscular energy use
- May reduce low-grade inflammation
- May modestly lower blood pressure
- Supports vascular health
- Reduces overall cardiac strain
- May improve edema in some
- Potential bone and cognitive benefits are being studied
- Overall support for healthy routines
- It assists your own physiology—no “magic bullet”
- Benefits may build over weeks to months
- Balanced diet + gentle activity improve outcomes
Weight-loss effectiveness
International trials of tirzepatide report an average weight loss of ~20%, and ~54.5% of participants achieved ≥25% loss (with continued therapy and lifestyle support).
Targets appetite, satiety, and glycemia—favoring steady change over harsh restriction.
Response varies with dose and habits. If nausea occurs, physicians can pause/escalate more gradually.
Regular meals, adequate protein, and light activity further improve composition and metabolic markers.
Reference: Jastreboff AM, et al. N Engl J Med. 2022;387(3):205–216.
Results are population averages; individual responses vary.
Recommended for
Helps reduce urges for snacking or late-evening overeating.
Fully online; nationwide delivery supports continuity.
Titrate at a comfortable pace with medical guidance.
Complements diet and activity to push past stalls.
Process to online prescription
Three simple steps on your phone. Same-day consults available; nationwide delivery.
How to use (follow your doctor’s instructions)
Self-inject once per week on the same weekday. Typically start at 2.5 mg.
Clean the site (abdomen, thigh, or upper arm). Rotate sites each time.
Press the pen vertically and inject as instructed. Keep it pressed for a few seconds after the signal.
Watch for nausea, vomiting, diarrhea/constipation, or abdominal pain. If severe symptoms occur, stop and seek care.
Pricing
Weight-loss Simulator
Visualize your path to a target weight, factoring Mounjaro use and lifestyle improvements (for reference only).
🎯 Mounjaro Weight-loss Simulator
Estimate your journey in about 3 minutes
📊 Projected timeline
Combination therapy (when appropriate)
Your physician may suggest add-ons based on your profile. Examples that can be synergistic:

Aim: Increase urinary glucose excretion to lower net calories.
Best for: Frequent snacks / limited time to exercise.
Note: Hydration and UTI/genital infection precautions.

Aim: Temper appetite impulses.
Best for: Evening overeating / compulsive snacking.
Note: Dry mouth, insomnia, constipation (avoid late dosing).

Aim: Reduce hepatic gluconeogenesis and improve insulin resistance.
Best for: Higher fasting glucose / weight-neutral preference.
Note: Start low due to GI tolerance.

Aim: Support bowel movements and fluid balance—useful for subcutaneous-fat type edema/constipation.
Best for: Constipation / edema / diet reset.
Note: Stop if GI upset occurs.
FAQ
Can I get Mounjaro via online consultation?
Notes:
• Under 18: parental consent is required.
• Existing conditions: please inform us during the teleconsultation.
How much does it cost? Is it covered by insurance?
• 2.5 mg: 6,000 JPY per pen (24,000 JPY / 4 pens)
• 5.0 mg: 9,500 JPY per pen (38,000 JPY / 4 pens)
• 7.5 mg: 12,000 JPY per pen (48,000 JPY / 4 pens)
• 10 mg: 15,000 JPY per pen (60,000 JPY / 4 pens)
• 12.5 mg: 19,000 JPY per pen (76,000 JPY / 4 pens)
• 15 mg: 23,000 JPY per pen (92,000 JPY / 4 pens)
Refrigerated shipping is free until 2025/10/31. Payments: credit card (VISA/Mastercard/JCB/AMEX) or bank transfer.
When will it arrive?
When might I feel an effect?
Any diet or exercise precautions while on Mounjaro?
What if I experience side effects?
Will I regain weight after stopping?
Can I self-inject if I’m needle-averse?
Can I take it with other medicines or supplements?
Is an online prescription safe?
How should I store it?
Where can I find the expiration date?
Can I inject immediately after taking it out of the fridge?
Can I purchase it like online shopping?
Where can I ask questions?
About the medicine used at our clinic (Mounjaro)
In Japan, tirzepatide is approved for type 2 diabetes. Use for obesity/weight management is currently off-label private care.
We procure via authorized pharmaceutical distributors and manage products appropriately.
Examples include Sanorex (anorectic) and Wegovy (semaglutide). Tirzepatide (Zepbound) received domestic obesity approval in Dec 2024.
Tirzepatide is approved for obesity in the US (FDA) and in Japan (Dec 27, 2024). Possible adverse events include acute pancreatitis, hypoglycemia, nausea, vomiting, abdominal pain, diarrhea, and constipation. Seek medical help if you feel unwell.
Because weight-management use is private/off-label, Japan’s governmental adverse-event relief schemes do not apply.